#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thalassaemia alpha Ehlers-Danlos syndrome Myotonic dystrophy Muscular dystrophy Brain stem glioma Ovarian cancer stage IV Chronic kidney disease Aplastic anaemia Richter's syndrome Acute lymphocytic leukaemia Squamous cell carcinoma of head and neck Spinal muscular atrophy Pulmonary alveolar haemorrhage Polyneuropathy Craniocerebral injury More trials…

    Learn about Rare Diseases

    Pleural mesothelioma malignant – Trials in Disease Systemic mastocytosis – Basic Information Mastocytosis – Basic Information Congenital hypotransferrinaemia – Treatment Rhabdomyosarcoma recurrent – Trials in Disease Anaplastic thyroid cancer – Diagnostics Angiosarcoma metastatic – Trials in Disease Brain stem glioma X-linked lymphoproliferative syndrome – Diagnostics Haemophilia A without inhibitors – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ocrelizumab Sodium Glycocholate Fluorescein Sodium Valemetostat Tosilate Dextromethorphan Hydrobromide Cimetidine Oxitriptan Davutamig Vonafexor Vesleteplirsen Pemetrexed Rct2100 Vudalimab Mecillinam Amitriptyline Poltreg-T1D Teprotumumab Linperlisib CANNABINOL VTX-002 More therapies…

    Learn about Your Condition

    Pancreatic neoplasm Neuromyopathy Primary hyperthyroidism Hypotonia Behavioural addiction Optic atrophy Postpartum haemorrhage Fallopian tube cancer stage IV Craniopharyngioma Left ventricular dysfunction Dementia B-cell lymphoma recurrent Bronchiectasis Bone marrow failure Stress urinary incontinence More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive breast cancer

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Human epidermal growth factor receptor negative
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Giredestrant
    France Germany Italy Spain

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Capecitabine
    • Doxorubicin Hydrochloride
    • Doxorubicin Hydrochloride, Liposomal
    France Germany Greece Hungary Italy Poland +1

  • Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    Investigated Drugs:
    • Capivasertib
    Belgium Germany Portugal

  • Study on the Effects of Ketorolac and Pregabalin in Patients Undergoing Surgery for Early Estrogen Receptor-Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • KETOROLAC
    • Pregabalin
    Belgium

  • Study on Oxybutynin and Venlafaxine for Reducing Hot Flashes in Women Undergoing Endocrine Therapy After Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone refractory breast cancer
    • Triple positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Leuprorelin
    • Venlafaxine
    • Oxybutynin
    The Netherlands

  • Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Capecitabine
    • Codeine Phosphate
    Belgium Czechia Denmark France Germany Greece +10
1 2 3 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!